Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Breast Neoplasms 145Lymphoma 104Lymphoma, Large B-Cell, Diffuse 76Sarcoma 62Hodgkin Disease 46Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Burkitt Lymphoma 35Triple Negative Breast Neoplasms 31Lymphoma, Non-Hodgkin 29Lymphoma, Mantle-Cell 27Leukemia 25Neoplasms 22Lymphoma, Follicular 22Neoplasm Metastasis 21Multiple Myeloma 21Neuroblastoma 20Carcinoma, Hepatocellular 18Ovarian Neoplasms 16Lymphoma, B-Cell 16Liver Neoplasms 14Urinary Bladder Neoplasms 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Osteosarcoma 12Lymphoma, T-Cell, Peripheral 11Lymphoma, Large-Cell, Anaplastic 11Inflammatory Breast Neoplasms 11Breast Neoplasms, Male 11Prostatic Neoplasms 10Dendritic Cell Sarcoma, Interdigitating 10Lymphoma, Large-Cell, Immunoblastic 9

Interventions

Cyclophosphamide 5Rituximab 3fludarabine phosphate 2fludarabine 2dacetuzumab 2cobomarsen 2blinatumomab 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Ifosfamide 2Etoposide 2Doxorubicin 2Carboplatin 2Busulfan 2pembrolizumab 1Vorinostat 1CLR1404 1Brentuximab Vedotin 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Immunoproliferative Disorders × Doxorubicin × Clear all
NCT02855359 2019-03-11

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Seagen Inc.

Phase 2 Terminated
24 enrolled 10 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00365274 2014-06-02

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 3 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡